Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Brigatinib: Phase III started

    Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Cambridge, Mass. Product: Brigatinib (AP26113) Business: Cancer Molecular target: Anaplastic lymphoma kinase (ALK); Epidermal growth factor receptor (EGFR) Description: Dual …

    Published on 4/18/2016
  • BTA585: Phase IIa started

    Aviragen Therapeutics Inc. (NASDAQ:BOTA), Alpharetta, Ga. Product: BTA585 Business: Infectious Molecular target: RSV F protein Description: RSV F protein inhibitor Indication: Treat respiratory syncytial virus (RSV) …

    Published on 4/18/2016
  • CAP-1002: Phase I/II ongoing

    Capricor Therapeutics Inc. (NASDAQ:CAPR), Beverly Hills, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: CAP-1002 Business: Cardiovascular Molecular target: NA Description: Allogeneic cardiosphere-…

    Published on 4/18/2016
  • Durvalumab: Phase I/II started

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Durvalumab (MEDI4736) Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Description: Human IgG1 mAb targeting PD-L1 …

    Published on 4/18/2016
  • Epidiolex cannabidiol: Phase III started

    GW Pharmaceuticals plc (LSE:GWP; NASDAQ:GWPH), Salisbury, U.K. Product: Epidiolex cannabidiol Business: Neurology Molecular target: Cannabinoid receptors Description: Oral liquid formulation of cannabidiol, a …

    Published on 4/18/2016
  • Glassia: Phase II started

    Baxalta Inc. (NYSE:BXLT), Deerfield, Ill. Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA), Ness Ziona, Israel Product: Glassia (IV Alpha-1 Antitrypsin (AAT)) Business: Transplant Molecular target: Elastase; Alpha-1 antitrypsin…

    Published on 4/18/2016
  • GLPG1690: Phase IIa started

    Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), Mechelen, Belgium Product: GLPG1690 Business: Pulmonary Molecular target: Autotaxin (ENPP2) (ATX) Description: Selective autotaxin (ENPP2; ATX) inhibitor Indication: Treat …

    Published on 4/18/2016
  • HMPL-689: Phase I started

    Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM), Hong Kong, China Product: HMPL-689 Business: Cancer Molecular target: Phosphoinositide 3-kinase (PI3K) delta Description: Phosphoinositide 3-kinase (PI3K) delta …

    Published on 4/18/2016
  • Lefamulin: Phase III started

    Nabriva Therapeutics AG (NASDAQ:NBRV), Vienna, Austria Product: Lefamulin (BC-3781) Business: Infectious Molecular target: NA Description: Pleuromutilin antibiotic Indication: Treat community-acquired bacterial …

    Published on 4/18/2016
  • LY3314814: Phase II/III ongoing

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: LY3314814, AZD3293 Business: Neurology Molecular target: Beta-site APP-cleaving enzyme 1 (BACE1); Beta-site APP…

    Published on 4/18/2016
  • MOR00208: Phase II started

    MorphoSys AG (Xetra:MOR), Martinsried, Germany Xencor Inc. (NASDAQ:XNCR), Monrovia, Calif. Product: MOR00208, MOR208 (formerly XmAb5574) Business: Cancer Molecular target: CD19 Description: Fc-optimized human mAb …

    Published on 4/18/2016
  • Motolimod: Phase I/II started

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. VentiRx Pharmaceuticals Inc., Seattle, Wash. Product: Motolimod (VTX-2337) Business: Cancer Molecular target: Toll-like receptor 8 (TLR8) Description: Small molecule …

    Published on 4/18/2016
  • Omadacycline: Completed Phase III enrollment

    Paratek Pharmaceuticals Inc. (NASDAQ:PRTK), Boston, Mass. Product: Omadacycline (formerly PTK 0796) Business: Infectious Molecular target: Ribosomal 30S subunit Description: Aminomethylcycline antibiotic Indication: …

    Published on 4/18/2016
  • Oral omecamtiv mecarbil: Phase II started

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Cytokinetics Inc. (NASDAQ:CYTK), South San Francisco, Calif. Product: Oral omecamtiv mecarbil Business: Cardiovascular Molecular target: Cardiac myosin Description: …

    Published on 4/18/2016
  • ParvOryx: Phase I/IIa started

    Oryx GmbH & Co. KG, Baldham, Germany Product: ParvOryx Business: Cancer Molecular target: NA Description: Parvovirus H1 (H-1PV), an apathogenic oncolytic rodent DNA virus Indication: Treat inoperable, metastatic …

    Published on 4/18/2016
  • [18F]-fluciclovine: Phase III started

    Blue Earth Diagnostics Ltd., London, U.K. General Electric Co. (NYSE:GE), Fairfield, Conn. Product: [18F]-fluciclovine (FACBC) Business: Diagnostic Molecular target: NA Description: Synthetic amino acid-based PET …

    Published on 4/11/2016
  • AG-120: Phase Ib/II started

    Agios Pharmaceuticals Inc. (NASDAQ:AGIO), Cambridge, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Product: AG-120 Business: Cancer Molecular target: Isocitrate dehydrogenase 1 (IDH1) Description: Inhibitor of mutated…

    Published on 4/11/2016
  • AG-221: Phase Ib/II started

    Agios Pharmaceuticals Inc. (NASDAQ:AGIO), Cambridge, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Product: AG-221 Business: Cancer Molecular target: Isocitrate dehydrogenase 2 (IDH2) Description: Inhibitor of mutated…

    Published on 4/11/2016
  • Ampion: Completed Phase III enrollment

    Ampio Pharmaceuticals Inc. (NYSE-M:AMPE), Englewood, Colo. Product: Ampion Business: Autoimmune Molecular target: NMDA receptor; Serotonin (5-HT2C) receptor Description: A cyclic aspartate-alanine dipeptide cleaved from…

    Published on 4/11/2016
  • Avelumab: Phase III started

    Merck KGaA (Xetra:MRK), Darmstadt, Germany Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Avelumab (MSB0010718C) Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Description: …

    Published on 4/11/2016
  • Carbidopa/levodopa GR: Phase III started

    Intec Pharma Ltd. (Tel Aviv:NTEC; NASDAQ:NTEC), Jerusalem, Israel Product: Carbidopa/levodopa GR (Accordion Pill Carbidopa/Levodopa) (AP-CDLD) Business: Neurology Molecular target: NA Description: Gastric retention …

    Published on 4/11/2016
  • DC Vaccine containing WT1/PRAME: Phase I/II started

    Medigene AG (Xetra:MDG1), Martinsried, Germany Product: DC Vaccine containing WT1/PRAME Business: Cancer Molecular target: Wilms tumor 1 (WT1); Preferentially expressed antigen in melanoma (PRAME) Description: …

    Published on 4/11/2016
  • Eflornithine/sulindac: Completed Phase III enrollment

    Cancer Prevention Pharmaceuticals Inc., Tucson, Ariz. Zeria Pharmaceutical Co. Ltd. (Tokyo:4559), Tokyo, Japan Product: Eflornithine/sulindac (DFMO/sulindac) (CPP-1X/sulindac) Business: Gastrointestinal Molecular target…

    Published on 4/11/2016
  • Fostamatinib disodium: Completed Phase III enrollment

    Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), South San Francisco, Calif. Product: Fostamatinib disodium (formerly R788, tamatinib fosdium) Business: Autoimmune Molecular target: Spleen tyrosine kinase (SYK) Description: …

    Published on 4/11/2016
  • IMCgp100: Phase I started

    Immunocore Ltd., Abingdon, U.K. Product: IMCgp100, ImmTAC-gp100 Business: Cancer Molecular target: Silver homolog (SILV) (PMEL17) (GP100) Description: Bispecific biologic comprising a T cell receptor (TCR) specific for …

    Published on 4/11/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993